CW July 2004
Volume 13Issue Number 7 July 2004 ISSN 10593802 Novel Anti-Angiogenesis Agent Combines With ChemotherapyPreliminary clinical trials in patients with advanced colorectal cancer of the combination of an oral anti-angiogenesis agent, PTK/ZK (Novartis/Schering AG, Berlin, Germany),with either the FOLFOX-4 or the FOLFIRI chemotherapy regimens suggest that the new agent may be a valuable adjunct therapy. Both trials found favorable response rates without added side effects, according to presentations at the 40th Annual Meeting of the American Society of Clinical Oncology.
Go to Previous Page Go to Next Page Source & Additional Reading William P. Steward, MD, Professor of Oncology at the University of Leicester, UK, 40th Annual Meeting of the American Society of Clinical Oncology presentation. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW July 2004Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
